HC-T6IV
Hayflick Partners
topical rapamycin, mTOR inhibition, micro-dose delivery
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companies
topical rapamycin, mTOR inhibition, micro-dose delivery
0-100 chain-logic scale · 15 dimensions · scored on public evidence
How to Stop or Reverse Skin Aging (2026) - Rapamycin Longevity News Rapamycin Longevity News How to Stop or Reverse Skin Aging (2026) RapAdmin January 10, 2026, 8:57pm #1 mTOR inhibitor for Skin Health and Rejuvenation This is a continuation of this thread: How to Reverse Skin Aging (2025) It seems like the evidence for significant benefits of topical rapamycin (i.e. rapamycin skin cream) gets stronger and stronger every year. There are now two companies that are developing topical skin creams using mTOR inhibitors for skin aging: RapaLogix: A New Rapalog for Skin Aging: Rapalogix Health RLX-2 … velopment that has some skin health and longevity benefit potential: Topical Co-application of Hyaluronan with Transdermal Drug Delivery Enhancers Attenuates Inflammatory and Neuropathic Pain 2 Likes LaraPo January 22, 2026, 4:16pm #4 Just wanted to share something that’s been working well for me in case it helps someone else. I’ve been using diluted Radiesse (both 1:0.5 and 1:1 ratios) over the past 6 mo—not for volume, but more for skin quality and subtle structure. I wasn’
Instagram Instagram Log In Sign Up Close Never miss a post from saraharronmdphd Sign up for Instagram to stay in the loop. Sign up Log in Tags chungfury.md saraharronmdphd • Follow More options saraharronmdphd 6w I am so excited to announce that Hayflick Therapeutics has been named the 2026 Startup of the Year at this week’s Biolabs Investor Day in Philadelphia! I’m honored to sit on the advisory board of this science backed skin health startup that has the mission to advance cellular aging therapies that are safe, measurable and designed for real world use. Congratulations to my colleague Dr.
Philadelphia Phoenix Announces Hayflick Therapeutics as 2026 Front Jersey Partner | WatchUFA Skip to main content WatchUFA Teams Schedule Standings Shop WatchUFA.tv Tickets Buy Tickets Stadium Info News Schedule Team Players Coaches Partners Youth Programs Pass The Disc Shop About Contact History Team Records Game Day Info VIP Medical Scheduling Rothman Schweiger Philadelphia Phoenix Announces Hayflick Therapeutics as 2026 Front Jersey Partner The Philadelphia Phoenix is proud to announce a new brand partnership with Hayflick Therapeutics, a biotechnology company developing cellular aging inte
Christina Lee Chung - Dermatologist at Schweiger Dermatology | The Org Platform Enrich Pricing Log in Sign up Schweiger Dermatology Christina Lee Chung Unverified CC Christina Lee Chung Dermatologist Contact Christina Lee Chung, MD, FAAD, currently serves as the Lead Founder and Inventor at Hayflick Partners, focused on developing FDA-approved topical therapeutics for aging. As President and Managing Partner of the Philadelphia Phoenix, significant revenue growth of over 1500% has been achieved under management. Chung also co-chairs the UFA Inclusion Initiative, aimed at enhancing diversity
Instagram Instagram Log In Sign Up Close Never miss a post from chungfury.md Sign up for Instagram to stay in the loop. Sign up Log in chungfury.md • Follow More options chungfury.md Edited • 7w I am beyond excited - still truly stunned🫢 - to announce Hayflick Therapeutics has been named the 2026 Startup of the Year at this week’s Biolabs Investor Day in Philadelphia. We were selected from hundreds of applicants to pitch in front of the industry’s leading venture capital and pharma investment arms, with over $8B in assets managed among them. And the pitch that resonated the most with them was
Hayflick Therapeutics - Hayflick Skip to content Our Story Our Team Perspectives Connect Our Story Our Team Perspectives Connect No Limits Who We Are Hayflick Therapeutics is a development-stage biotechnology company advancing the proven use of rapamycin through disciplined, FDA-aligned innovation. Positioned at the intersection of aesthetics and healthspan, Hayflick is advancing a first-in-class platform targeting the mTOR pathway to bring cellular aging interventions to a broad and underserved global market. Through localized, micro-dose delivery, our platform enables root cause, molecular-l … ientific Advisory Board Sarah Arron , MD, PhD Board-certified dermatologist and fellowship-trained Mohs micrographic surgeon with over fifteen years of experience in dermatologic surgery and aesthetic dermatology. She trained at UCSF and served on faculty for twelve years, leading translational skin cancer research and holding senior clinical leadership roles. At Hayflick, she provides guidance on dermatologic strategy and the clinical integration of emerging therapeutics. Cl